We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Scholar Rock Holdings Corporation | NASDAQ:SRRK | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.34 | -4.04% | 8.07 | 8.08 | 8.50 | 8.42 | 8.05 | 8.37 | 670,606 | 23:55:38 |
From Dec 2023 to Jun 2024
By Denny Jacob
Scholar Rock Holding said the Food and Drug Administration cleared its investigational new drug application for its Phase 2 trial of apitegromab to treat obesity in patients taking a GLP-1 receptor agonist.
The late-stage biopharmaceutical company said trial initiation is on track for mid-2024 and data from the trial is expected in mid-2025.
In parallel, Scholar Rock is developing SRK-439 also to treat obesity. It plans to file an investigational new drug application for SRK-439 in 2025.
"The FDA's acceptance of our IND application to study apitegromab in obesity allows us to assess the effect of our highly selective myostatin inhibitor on preserving lean muscle mass, and safety and tolerability of our approach when combined with a GLP-1 RA," said Chief Executive Jay Backstrom.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 23, 2024 08:47 ET (13:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Scholar Rock Chart |
1 Month Scholar Rock Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
